Technology Profits Confidential

The world of tech and biotechnology will provide endless opportunity for growth and wealth for investors who know where to look.

Technology Profits Confidential is your one-stop shop for the companies of tomorrow's technology... and how you can profit from them.

Geron Focusing on Oncology Programs

Earlier this week, Geron announced that it would discontinue its stem cell clinical trials. It intends to focus its research efforts on its oncology programs. While disappointing for those of us hoping to see Geron continue to advance its stem cell programs, this sort of action isn't unusual for small biotech companies. With scarce resources, putting programs with longer time horizons on hold in favor of lower-hanging fruit that can pay off in the nearer term makes economic sense. It helps prevent the dilution of the shares, and preserves capital for advancing programs that can produce revenues sooner. It is a shareholder-friendly move.

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!


Technology Profits Confidential

With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.

Login

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, FDA Profit Alert, and Technology Profits Daily. Ray has been with Seven Figure Publishing since 2010. In 2019, his closed positions in Technology Profits Confidential outperformed the S&P500 by 50%.

View More By Ray Blanco